Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16502459 | 0.90 | XDH (0.44) | PLA2G2DSLC22A12XDHPTPN1ABL1 | |
| SCHEMBL16502482 | 0.86 | PARP1 (0.42) | MRGPRX4ABL1 | |
| SCHEMBL16509448 | 0.86 | PLA2G2D (0.47) | PLA2G2DSLC22A12XDHPTPN1SLC16A3 | |
| SCHEMBL16502465 | 0.85 | SLC22A12 (0.46) | PLA2G2DSLC22A12XDHPTPN1 | |
| SCHEMBL16509500 | 0.84 | SLC9A1 (0.44) | — | |
| SCHEMBL7569348 | 0.83 | XDH (0.48) | SLC22A12XDH | |
| SCHEMBL7919876 | 0.83 | PLA2G2D (0.49) | PLA2G2DMRGPRX4PTPN1 | |
| SCHEMBL7918688 | 0.81 | PLA2G2D (0.47) | PLA2G2DMRGPRX4PTPN1 | |
| SCHEMBL16509453 | 0.81 | PLA2G2D (0.42) | PLA2G2DSLC22A12MRGPRX4PTPN1SLC16A3 | |
| SCHEMBL16502490 | 0.80 | PLA2G2D (0.49) | PLA2G2DPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306621-A1 | ACYLGUANIDINE DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2011-12-15 | — | — | US | disclosed |
| US-20110306621-A1 | ACYLGUANIDINE DERIVATIVES | ASTELLAS PHARMA INC. (JP) | 2011-12-15 | — | — | US | disclosed |
| EP-2394987-A1 | ACYLGUANIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010090304-A1 | ACYLGUANIDINE DERIVATIVE | アステラス製薬株式会社 (JP) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306621-A1 | ACYLGUANIDINE DERIVATIVES | HTR5A, HTR2A, HTR1A | PLA2G2D 841/4885SLC22A12 1344/4885SYK 2146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.